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Abstract
Background/Aim. Ovarian cancer is the leading cause of
death from gynecologic malignancies. Risk of malignancy in-
dex (RMI) is recommended in assessment of patients with
adnexal masses. The aim of this study was to verify the effec-
tiveness of the RMI in the discrimination between benign le-
sions and malignant adnexal masses in clinical practice.
Methods. Ultrasounds were performed for all the patients
and menopausal status, CA125 level and calculated RMI were
defined. All the patients were divided into 3 groups depend-
ing on RMI (< 25, 25–200, > 200). After operations all ad-
nexal masses were analyzed histopathologically (HP) and then
sensitivity, specificity and predictive value of RMI were cal-
culated. Results. Out of a total of 81 patients involved be-
nign tumor had 51 (62.96%) and malignant 30 (37.04%) of
the patients. The average value of CA125 in the group of pa-
tients with benign adnexal masses was 68.3 U/mL and in the
group of patients with malignant adnexal masses it was
581.95 U/mL. In the group of patients with benign adnexal
masses the average RMI was 284.9 and in the group of pa-
tients with malignant adnexal masses RMI was 469.2. All the
results showed a positive correlation between both HP cate-
gories and RMI categories. The more malignant HP result
produced higher RMI and the cut off value was RMI = 200.
Sensitivity of RMI was 83.33%, specificity was 94.12%, posi-
tive predictive value was 89.29% and negative predictive
value was 90.57%. Conclusion. Our study showed that RMI
is very reliable in differentiation benign from malignant ad-
nexal masses.
Key words:
ovarian neoplasms; diagnosis, differential; risk
assessment; ultrasonography; menopause; histological
techniques; postoperative period.
Apstrakt
Uvod/Cilj. Karcinom ovarijuma je vodeći uzrok smrti od
ginekoloških maligniteta. U istraživanju bolesnica sa adnek-
salnim masama koristi se indeks rizika od malignosti (RMI).
Cilj studije bio je ispitivanje efektivnosti RMI kao metode za
razlikovanje benignih od malignih adneksalnih tumora u kli-
ničkoj praksi. Metode. Svim bolesnicama urađen je ultraso-
nografski pregled organa male karlice, određen menopau-
zalni status i nivo tumorskog markera CA125, a zatim izra-
čunat RMI. Bolesnice su bile podeljene u tri grupe prema
vrednosti RMI (< 25, 25–200, >  200). Posle operativnog
zahvata adneksalni tumori su histopatološki (HP) analizira-
ni, a zatim su izračunate vrednosti senzitivnosti, specifično-
sti i prediktivne vrednosti RMI. Rezultati. Od ukupno 81
ispitane bolesnice benigni tumor imala je 51 ispitanica
(62,96%), dok je njih 30 (37,04%) imalo maligni tumor. Pro-
sečna vrednost CA125 u grupi bolesnica sa benignim adnek-
salnim tumorima bila je 68,3 U/mL, dok su one sa malignim
adneksalnim tumorima imale vrednost CA125 od 581,95
U/mL. Kod bolesnica sa benignim tumorima prosečan RMI
bio je 284,9, a u grupi sa malignim tumorima 469,2. Rezul-
tati pokazuju pozitivnu korelaciju između obe kategorije HP
nalaza i kategorija RMI: što je veći RMI, HP nalaz pokazuje
veću malignost, a značajna granična vrednost RMI je 200.
Na osnovu rezultata ove studije, senzitivnost RMI iznosi
83,33%, specifičnost 94,12%, dok je pozitivna prediktivna
vrednost 89,29%, a negativna prediktivna vrednost 90,57%.
Zaključak. Naša studija pokazala je da je RMI veoma pou-
zdan za diferencijaciju benignih od malignih adneksalnih
tumora.
Ključne reči:
jajnik, neoplazme; dijagnoza, diferencijalna; rizik,
procena; ultrasonografija; menopauza; histološke
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Introduction
Ovarian cancer is a leading cause of death among gyne-
cological malignant tumors. Treatment efficiency in patients
with ovarian cancers could be increased by standardization
of preoperative evaluation. Jacobs et al. 
1 have introduced
risk of malignancy index (RMI) and that was the first diag-
nostic model which has combined demographic, sonographic
and biochemical parameters for investigating patients with
adnexal masses. RMI was modified by Tingulstad et al. 
2, 3
for the first time in 1996 (RMI2) and for the second time in
1999 (RMI3). These three versions of RMI were assessed in
many prospective and retrospective clinical studies. Yama-
moto et al. 
4 made even RMI4, but its validity is due to be
confirmed in future studies. The RMI value of 200 has been
proven to be the best for distinction of benign from malig-
nant adnexal masses, with the high level of sensitivity (51%–
90%) and specificity (51%–97%)
 5, 6.
The aim of the study was to evaluate the risk of malig-
nancy index efficiency in differentiation benign from malig-
nant adnexal tumors in clinical practice.
Methods
The study involved all patients with adnexal tumors
who were hospitalized at the Institute of Gynecology and
Obstetrics, Clinical Center of Serbia during the first six
months of 2010. Ultrasonographic examination of pelvic or-
gans was performed, menopausal status and level of cancer
antigen 125 (CA125) were assessed and finally RMI was
calculated for all the patients. RMI was calculated using the
formula: RMI = U × M × CA125. In the formula U repre-
sents the ultrasound index. Multilocular and bilateral tumors,
the presence of solid parts in tumor, metastasis and ascites
are marked with one point each. The sum of these points, are
scored so that in the formula U 0 = 0 points, U 1 = 1 points,
U 2–5  = 3 points. In the formula M represents menopausal
status (1 for premenopausal and 3 for postmenopausal
women). Values of CA125 are taken in all patients prior to
surgery. The patients were divided into three groups accord-
ing to the RMI values (low risk < 25, intermediate risk 25–
200, high risk > 200). After surgery, histopathological (HP)
findings of excised tumors were analyzed in order to deter-
mine the final diagnosis and the stage the disease. Finally,
based on the standard formulas, sensitivity [(true positive /
true positive + false negative) × 100], specificity [(true
negative / true negative + false positive) × 100], positive
[(true positive / true positive + false positive) × 100] and
negative [(true negative / true negative + false negative) ×
100] predictive values of RMI, as a test which could indicate
tumor malignancy, were calculated. For statistical analysis of
the achieved data standard methods of data description
(mean values, variability measures such as confidence inter-
val and standard deviation) as well as the tests for examining
the significance of correlations and differences between
achieved data (chi- square test, Fisher T-test and Spearman
Rank correlation) were used. For statistical data analysis
SPSS 15 computer program was used.
Results
The study involved 81 patients, out of which 51
(62.96%) were still in the reproductive period, while 30
(37.04%) were in the menopause. Out of all analyzed pa-
tients benign tumor had 51 (62.96%) and malignancy 30
(37.04%) women. In the group of premenopausal women be-
nign tumor was registered in 38 (74.51%) and malignancy in
13 (25.5%) patients. In the group of postmenopausal women
benign tumor was registered in 13 (43.33%) and malignant in
17 (56.67%) patients. From all benign tumors ovarian cyst
was the most frequent, while from the malignant tumors ade-
nocarcinoma was found to be the most usual (Figure 1). The
HP diagnoses of benign adnexal masses are shown in Table
1while Table 2 shows HP diagnoses of malignancy.
Fig. 1 – Adnexal tumors’ histological findings of all the
investigated patients
1– benign ovarian cyst; 2 – adenocarcinoma; 3 – endometriosis; 4 –other
The average age of the investigated patients with be-
nign tumors was 38.3 years, whereas, the average age of the
investigated patients with malignant tumors was 51.45 years,
which was significantly different (p = 0.001, p < 0.05). The
average value of CA125 in the group of patients with benign
adnexal tumors was 68.3 U/mL, while in the group of those
with malignant tumors it was 581.95 U/mL. However, there
were no significant differences in CA125 values concerning
categories of HP findings (benign, malignant) (p = 0.342, p >
0.05). These data are shown in the Table 3.
Multilocular changes with solid tumor components were
registered in 5 (6.71%) of the patients who were all premeno-
pausal. Only multilocular changes were registered in 24
(29.63%) of the patients, 14 pre- and 10 postmenopausal. Tu-
mor had only solid parts in 18 (22.22%) patients, 8 pre- and 10
postmenopausal. Metastases were registered in 11 (13.58%) of
the patients, out of which 6 were postmenopausal and ascites
was registered in 13 (16.05%) of the patients, out of which
only 4 were premenopausal. Tumors were present on both
ovaries in 13 (16.05%) women, 8 pre- and 5 postmenopausal.
Using the given formula, RMI was calculated for each
patient. In the group of patients with benign adnexal masses
average RMI was 284.9 (min = 0, max = 2,889), while in the
group with malignant changes it was 469.2 (min  = 0,
max  =  122,607). Relation between RMI, HP findings and
menopausal status is shown in the Table 4.Volumen 68, Broj 7 VOJNOSANITETSKI PREGLED Strana 591
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Table 1
Histopathological (HP) findings in the patients with benign adnexal tumors
Patients
HP diagnosis Total number
(%) of patients
Percentage of
benign findings Premenopausal
n (%)
Postmenopausal
n (%)
Cystis haemorrhagica ovarii 3 (3.7) 5.88 2 (3.92) 1 (3.24)
Cystis corporis lutei 3 (3.7) 5.88 3 (5.88) 0
Cystis hydatidosa Morgagni 4 (4.94) 7.84 4 (7.85) 0
Cystis symplex ovarii 9 (11.11) 17.65 6 (11.76) 3 (10.00)
Cystis folicularis ovarii 3 (3.7) 5.88 3 (5.88) 0
Cystis endometriotica 13 (16.05) 25.49 10 (19.61) 3 (10.00)
Fibroadenoma ovarii 2 (2.47) 3.92 2 (3.92) 0
Cystadenoma serosum 4 (4.94) 7.84 2 (3.92) 2 (6.67)
Cystadenoma mucinosum 4 (4.94) 7.84 2 (3.92) 2 (6.67)
Cystadenoma mixtus benignum 1 (1.23) 1.96 1 (1.97) 0
Tu Brener benignum 1 (1.23) 1.96 0 1 (3.24)
Teratoma cysticum benignum – cystis
dermoidalis bill 4 (4.94) 7.84 3 (5.88) 1 (3.24)
Table 2
Histopathological (HP) findings in the patients with malignant adnexal tumors
Patients
HP diagnosis Total number (%)
of patients
Percentage of
malignant find-
ings
Premenopausal
n (%)
Postmenopausal
n (%)
Adeno Ca endometrioides ovar. 5 (6.18) 16.67 2 (3.92) 3 (10.00)
Adeno Ca papillare serosum 4 (4.94) 13.33 1 (1.97) 3 (10.00)
Adeno Ca serosum ovarii 5 (6.18) 16.67 2 (3.92) 3 (10.00)
Adeno Ca
slabodiferentovan 4 (4.94) 13.33 2 (3.92) 2 (6.67)
Tu mixtus malignus – CaSa 1 (1.23) 3,33 0 1 (3,24)
Yolk sac tumor ovarii Ic 1 (1.23) 3.33 0 1 (3.24)
Fibrosarcoma ovarii 2 (6.67) 6.67 0 2 (6.67)
Atipicaly proliferating serosus bor-
derline Tu ovarii 4 (4.94) 13.33 3 (5.88) 1 (3.24)
Atipicaly proliferating mucosus bor-
derline Tu ovarii 4 (4.94) 13.33 3 (5.88) 1 (3.24)
Table 3
Age and CA125 levels in the patients with benign and malignant adnexal tumors
Benign tumors Malignant tumors
Parameters
min max average min max average
Age (years) 16 72 38.3 16 82 51.45
CA125 (U/mL) 4.2 963 68.3 2.4 13623 581.95
Table 4
Risk of malignancy index (RMI) categories in the investigated patient groups
RMI
< 25 25–200 > 200
HP diagnosis
Prem
n (%)
Postm
n (%)
Total
n (%)
Prem
n (%)
Postm
n (%)
Total
n (%)
Prem
n (%)
Postm
n (%)
Total
n (%)
BT (n = 51) 26 (50.98%) 5 (16.67%) 31(60.78%) 10 (19.61%) 7 (23.33%) 17 (33.34%) 2 (3.92%) 1 (3.33%) 3 (5.88%)
MT (n = 30) 1 (1.96%) 4 (13.33%) 5 (16.67%) 8 (15.69%) 4 (13.33%) 12 (40%) 4 (7.84%) 9 (30%) 13 (43.33%)
Sum (n = 81) 27 (52.94%) 9 (30%) 36 (44.44%) 18 (35.29%) 11 (36.37%) 29 (35.81%) 6 (11.76%) 10 (33.33%) 16 (19.75%)
HP – histopathology; BT – benign tumors; MT – malignant tumors; Prem – premenopausal; Postm – postmenopausalStrana 592 VOJNOSANITETSKI PREGLED Volumen 68, Broj 7
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Data shown in Table 4 indicate a positive correlation
between both categories of HP findings (benign, malignant)
and categories of RMI in all the examined women. This cor-
relation shows that with an increase of RMI values, HP
findings are more frequently malignant and that the signifi-
cant cut off value of RMI is 200 (Roxy = 0.428;  df = 78;
p = 0.000; p < 0.01).
There were 3 patients with benign tumors and RMI
higher than 200. Those were false positive cases. On the
other hand, 5 patients with malignant tumors had RMI less
than 200. Those were false negative cases. In the group of
premenopausal women false positive results were 2 and
false negative 1, while in the group of postmenopausal
women there was 1 false positive result and 4 false nega-
tive results. The most frequently misdiagnosed were bor-
derline tumors (3 out of 8) or low differentiated tumors (1
out of 4) as well as endometriotic cysts (2 out of 13) and
benign mucinous cystadenomas (2 out of 8). Therefore,
RMI sensitivity is 83.33%, specificity 94.12%, while the
positive predictive value is 89.29% and the negative pre-
dictive value is 90.57%.
Discussion
The investigated patients from our population more fre-
quently had benign adnexal masses, which were more fre-
quent in premenopausal women. On the other hand, patients
who had malignant tumors were significantly older than
those with benign masses and therefore, in postmenopausal
group malignant tumors were the most usual.
Our study shows that the risk for malignancy of adnexal
tumor based on RMI statistically significantly corresponds
with postoperatively obtained HP findings. Among the pa-
tients we investigated, there were a lot of cases of benign
tumors and high CA125 values. It is well known that the lev-
els of CA125 in premenopausal women can vary regarding
the phase of menstrual cycle and that the peak values are
during menstrual bleeding 
7. Also, entities such as endome-
triosis and pelvic inflammatory disease can be the reason for
high blood levels of CA125 
8. In our study, out of all benign
tumors 25.49% were endometriotic cysts and that lead to the
increase of CA125 levels in the group of women with benign
adnexal masses.
On the other hand, borderline tumors were sorted in the
group of malignant tumors and they were present in 26.66%
of the patients with malignant tumors. That might have influ-
enced a bit lower the average values of CA125 in the group
of patients with malignant adnexal masses. Nevertheless, ac-
cording to the data from the literature, values of CA125 are
still of high importance in evaluation of adnexal masses, and
therefore must not be disregarded
 9–13. Concerning the above
mentioned, RMI has shown to be a significant factor in rou-
tine clinical practice and therefore we evaluated its efficiency
very precisely.
Based on the RMI analysis that we have done, it can be
concluded that all aspects of RMI efficiency are satisfactory
(high sensitivity, specificity, positive predictive value and
negative predictive value), which can indicate significance of
RMI in discrimination between benign and malignant ad-
nexal tumors. The results of our study are in correlation with
the data from the literature
 14, 15.
However, when we compare the investigated parameters,
it can be seen that higher values are achieved for specificity
and negative predictive value than for sensitivity and positive
predictive value. Good specificity means that test will always
disregard negative findings, i.e. in our case that benign tumors
will always have low RMI values. That is also confirmed by
high negative predictive values. Tests with better specificity
are more useful in early diagnostic phases and in population
screening and RMI calculation and evaluation is used pre-
cisely in those cases. If we compare pre- and postmenopausal
women, RMI is more sensitive and specific for the premeno-
pausal group. On the other hand, in both groups as well as in
all the patients examined together, a higher specificity was ob-
served. On the contrary, a positive predictive value had maxi-
mal values in the group of postmenopausal women, which in-
dicates that high RMI of the patients from this group will usu-
ally (92.86% cases) really be a sign of malignant adnexal tu-
mor. A bit lower sensitivity indicates that final diagnostics can
not be based only on RMI, as there is still a chance that this
method does not diagnose the presence of malignant tumor.
Conclusion
Our study confirms that RMI is very reliable for differ-
entiation between benign and malignant adnexal masses.
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